TrialThe oncologist2024

A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.

Hanna K Sanoff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.